Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mirena is a hormone-releasing intrauterine device (IUD) that contains the active ingredient levonorgestrel, a synthetic progestin. It is a T-shaped plastic device inserted into the uterus by a healthcare provider. Mirena provides long-term contraception for up to 8 years and is also approved for the treatment of heavy menstrual bleeding (menorrhagia) in women who choose an IUD for contraception, with efficacy for up to 5 years[1][2][4][5][7]. The mechanism of action involves local release of levonorgestrel in the uterine cavity, which thickens cervical mucus to inhibit sperm passage, alters the endometrial lining to prevent implantation, and may partially suppress ovulation in some users[3][4][6]. Only small amounts of hormone reach systemic circulation. Mirena does not contain estrogen and should not be used as emergency contraception.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mirena.